Glaxo Begins Phase III Study Of Triple Combination Therapy In Asthma Patients

(RTTNews) - GlaxoSmithKline plc (GSK.L, GSK) announced the company and Innoviva, Inc. (INVA) announced the start of a phase III study investigating the effects of once-daily closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) when compared to therapy with the once-daily dual combination therapy, Relvar/Breo (FF/VI), as a treatment for patients with asthma.

In the phase III study, termed CAPTAIN, the primary endpoint is the change from baseline in trough Forced Expiratory volume in 1 second at 24 weeks of treatment and the key secondary endpoint is the annualized rate of moderate/severe asthma exacerbations. Other secondary endpoints are assessing health-related quality of life and symptom control.